Boardroom Alpha
Boardroom Alpha
SGHT · Current Report (Form 8-K) · Filed June 5, 2026

Sight Sciences Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 5, 2026
Period
Jun 4, 2026
Ticker
SGHT
Accession
0001193125-26-259546
Boardroom Alpha · Filing insights

Gerhard Burbach and Staffan Encrantz elected as Class II directors; Deloitte & Touche ratified as auditors for 2026.

About Sight Sciences Inc
Market cap
$471M
1Y TSR
+88.8%
3Y TSR
+0.8%
Board grade
B-
Sector
Healthcare
CEO
Paul Badawi
Last annual meeting: Jun 4, 2026 · View full Sight Sciences Inc profile →
8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2026

 

 

Sight Sciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40587

80-0625749

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4040 Campbell Avenue

Suite 100

 

Menlo Park, California

 

94025

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 877 266-1144

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

SGHT

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On June 4, 2026, Sight Sciences, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). There were 54,403,542 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting at the close of business on April 8, 2026, the record date for the Annual Meeting (the “Record Date”). At the Annual Meeting, 41,456,258 shares of Common Stock were present virtually or represented by proxy, representing approximately 76.2% of the Common Stock outstanding on the Record Date.

 

Set forth below are the voting results for the proposals considered and voted upon at the Annual Meeting, each of which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 22, 2026.

 

Proposal 1 – Election of two Class II directors to serve as directors of the Company until the annual meeting of stockholders to be held in 2029, or until each such director’s respective successor has been duly elected and qualified, or until each such director’s earlier death, resignation or removal.

 

Name of Director

For

Withheld

Broker Non-Votes

Gerhard Burbach

24,961,185

2,877,580

13,617,493

Staffan Encrantz

 

 

23,901,624

 

 

 

3,937,141

 

 

 

13,617,493

 

 

Proposal 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

 

For

Against

Abstain

Broker Non-Votes

41,059,471

7,892

388,895

-

 

Based on the foregoing votes, Gerhard Burbach and Staffan Encrantz were elected as Class II directors, and the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was duly ratified.

 

No other matters were presented for consideration or stockholder action at the Annual Meeting.

 

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Sight Sciences, Inc.

 

 

 

 

Date:

June 5, 2026

By:

/s/ James Rodberg

 

 

 

James Rodberg

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Sight Sciences Inc (SGHT)

Reference

Frequently asked questions

When did Sight Sciences Inc file this 8-K?
Sight Sciences Inc (SGHT) filed this Current Report (Form 8-K) with the SEC on June 5, 2026. The accession number assigned by EDGAR is 0001193125-26-259546.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Gerhard Burbach and Staffan Encrantz elected as Class II directors; Deloitte & Touche ratified as auditors for 2026. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Sight Sciences Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Sight Sciences Inc has filed under CIK 1531177, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer